<DOC>
	<DOCNO>NCT00482430</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness investigational drug treatment cognitive impairment patient schizophrenia .</brief_summary>
	<brief_title>MK0557 Treatment Cognitive Impairment Patients With Schizophrenia ( 0557-027 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<criteria>Patient clinically stable , current antipsychotic medication least 3 month current dose 2 month Patient 6th grade read level well complete least 6 year formal education Females pregnant , child agree remain abstinent use acceptable birth control throughout study Patient stable living arrangement least 3 month prior study start Patient general good health base screen assessment Patient major disease/disorder may interfere cognitive testing ( mental retardation ) and/or pose risk upon study participation Patient history head trauma loss consciousness great 15 minute Patient warfarin treatment , MAO inhibitor , clonazepam , clozapine St. John 's wort within 1 month screen Patient ECT treatment within 6 month screen Patient require treatment antihistamine certain medication list protocol Patient history liver disease active within last 2 year , history cancer within past 5 year Patient history alcohol drug dependence within past year alcohol drug abuse within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Undifferentiated schizophrenia</keyword>
	<keyword>Residual schizophrenia</keyword>
</DOC>